Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates
07:35pm, Thursday, 03'rd Nov 2022
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
08:05pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program hav
GSK Gears Up to Report Q3 Earnings: What's in the Cards?
05:13pm, Monday, 31'st Oct 2022 Zacks Investment Research
Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
10:06pm, Friday, 28'th Oct 2022 GlobeNewswire Inc.
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
06:06pm, Friday, 28'th Oct 2022
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter en
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
09:15pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Gilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir begins dosing participants in Phase 2 clinical trial for new type of flu shot
08:32am, Tuesday, 18'th Oct 2022
Vir Biotechnology Inc. VIR, +4.50% said Tuesday that it began dosing participants in a Phase 2 clinical trial evaluating its experimental monoclonal antibody to prevent illness from influenza A. The i
Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
02:56am, Wednesday, 12'th Oct 2022
Updated results from Part A of the phase 2 MARCH study using both VIR-2218 and VIR3434 for Hepatitis B treatment are expected in the 2nd half of 2022. Results from the ongoing phase 2 study using VIR-
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
08:03pm, Tuesday, 11'th Oct 2022 GlobeNewswire Inc.
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head o
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
04:33pm, Friday, 07'th Oct 2022 Zacks Investment Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
02:18pm, Friday, 07'th Oct 2022
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
02:28pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
01:15pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
10:32am, Wednesday, 05'th Oct 2022
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
09:52am, Tuesday, 04'th Oct 2022
Vir Biotechnology inked a deal Tuesday worth up to $1 billion for its experimental flu treatment, leading Vir stock to surge. The post The Next Pandemic?
